arrow
C

Christos Demosthenous

g. papanicolaou hospital
H指数:12
被引数:483

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Longitudinal Cognitive Assessment After CAR-T Cell Immunotherapy: A Prospective Cohort Study

CAR-T细胞免疫疗法后的纵向认知评估:一项前瞻性队列研究

Cancers
IF4.4
2026-06-010
OA
Treosulfan-Based Conditioning Regimens for Allogeneic Hematopoietic Cell Transplantation in Acute Myeloid Leukemia and Other Myeloid Malignancies

基于TREOSULFAN的异基因造血细胞移植预处理方案在急性髓系白血病和其他髓系恶性肿瘤中的应用

2025-10-290
OAAI
Soluble Urokinase-Type Plasminogen Activator Receptor (suPAR) and Growth Differentiation Factor-15 (GDF-15) Levels Are Significantly Associated with Endothelial Injury Indices in CAR-T Cell Recipients

可溶性尿激酶型纤溶酶原激活剂受体(suPAR)和生长分化因子-15(GDF-15)水平与CAR-T细胞受体受者的内皮损伤指标显著相关。

BLOOD
IF23.1
2024-11-050
PRE
Genetic Susceptibility in Sinusoidal Obstruction Syndrome/Veno-Occlusive Disease

遗传易感性在窦状梗阻综合征/静脉闭塞性疾病中的作用

BLOOD
IF23.1
2024-11-050
PRE
Therapeutic strategies and treatment sequencing in patients with chronic lymphocytic leukemia: An international study of ERIC, the European Research Initiative on CLL

慢性淋巴细胞白血病患者的治疗策略和治疗顺序: 欧洲CLL研究计划ERIC的国际研究

2024-09-170
OAAI
Additional booster doses in patients with chronic lymphocytic leukemia induce humoral and cellular immune responses to SARS-CoV-2 similar to natural infection regardless ongoing treatments: A study by ERIC, the European Research Initiative on CLL
2024-01-241
OAAI
Other malignancies in the history of CLL: an international multicenter study conducted by ERIC, the European Research Initiative on CLL, in HARMONY

CLL历史上的其他恶性肿瘤: ERIC进行的一项国际多中心研究,欧洲CLL研究倡议,和谐

2023-11-016
OAAI
The evolving landscape of COVID-19 and post-COVID condition in patients with chronic lymphocytic leukemia: A study by ERIC, the European research initiative on CLL

慢性淋巴细胞白血病患者新型冠状病毒肺炎和COVID后病情的演变: 欧洲CLL研究计划ERIC的一项研究

2023-09-2911
OAAI
COVID-19 severity and mortality in patients with CLL: an update of the international ERIC and Campus CLL study

CLL患者的新型冠状病毒肺炎严重程度和死亡率: 国际ERIC和CLL研究的最新进展

LEUKEMIA
IF13.4
2021-11-0169
OAAI